MeSH tree: D04.210.500.365.415.248.660
Anti-estrogenic therapies can suppress the growth of cancer that does not express estrogen receptors; when combined with immune checkpoint inhibitor therapies, they halt tumor progression in mice models.
Aug 21, 2023
0
59
The next-generation selective estrogen receptor degrader (SERD) camizestrant improved progression-free survival, compared with fulvestrant (Faslodex), in patients with hormone receptor-positive, HER2-negative breast cancer ...
Dec 8, 2022
0
28
In patients with hormone receptor (HR)-positive, HER2-negative tumors resistant to aromatase inhibitors, addition of the investigational AKT inhibitor capivasertib to fulvestrant (Faslodex) doubled the median progression-free ...
Dec 8, 2022
0
26
The progression of certain types of breast cancers can be slowed by identifying a particular genetic mutation and then quickly adapting treatment, a first-of-its-kind study showed on Friday.
Sep 30, 2022
0
28
